Stockholders Approve Reverse Split, Dilutive Share Issuances, and Name Change

summarizeSummary

Aditxt stockholders approved a wide-ranging reverse stock split, significant share issuances for past financings, and an expanded equity incentive plan, alongside a company name change, as the company navigates Nasdaq compliance issues.

check_boxKey Events · Corporate Governance and Compliance · ADTX

• Reverse Stock Split Approved

  Stockholders granted the board discretionary authority to effect a reverse stock split at a ratio between 1-for-5 and 1-for-250. This follows the Nasdaq compliance extension granted on January 28, 2026.

• Dilutive Share Issuances Approved

  Approval was granted for the issuance of common stock underlying Series A-1 Convertible Preferred Stock (December 2023), Series C-1 Convertible Preferred Stock and warrants (May and August 2024), and July 2024 warrants.

• Equity Incentive Plan Significantly Expanded

  The 2021 Omnibus Equity Incentive Plan was amended to increase the number of shares of common stock issuable thereunder from 3 to 350,000 shares, representing substantial potential future dilution.

• Company Name Change Approved

  Stockholders approved a non-binding, advisory vote to change the company's name from "Aditxt, Inc." to "bitXbio, Inc."

auto_awesomeAnalysis · ADTX · Life Sciences

Aditxt, Inc. stockholders approved several critical proposals at its reconvened special meeting, including a broad discretionary reverse stock split (1:5 to 1:250) and the issuance of common stock underlying previously issued convertible preferred stock and warrants. These approvals are highly significant for the nano-cap company, especially the reverse split, which is a direct measure to address the Nasdaq listing compliance issues highlighted in the January 28, 2026 filing. The approval of substantial share issuances for past financings and a significantly expanded equity incentive plan (from 3 to 350,000 shares) indicates considerable potential future dilution for existing shareholders. The company also received approval to change its name to "bitXbio, Inc.", signaling a potential rebranding effort amidst its financial and compliance challenges.